TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 36.62

Change

0.00 (0.00)%

Market Cap

USD 1.39B

Volume

0.31M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
PCVX Vaxcyte Inc

N/A

USD 14.16B

ETFs Containing TARS

FXZ First Trust Materials Alp.. 4.83 % 0.64 %

N/A

N/A
SLX VanEck Steel ETF 4.76 % 0.56 %

N/A

N/A
SMLL Harbor ETF Trust 3.46 % 0.28 %

N/A

N/A
PICK 1.50 % 0.39 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.05 % 0.15 %

N/A

N/A
QVMM Invesco Exchange-Traded F.. 0.64 % 0.00 %

N/A

USD 0.33B
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.63 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.63 % 0.00 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

N/A

N/A
XME SPDR® S&P Metals and Min.. 0.00 % 0.35 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 80.84% 61% D- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.84% 61% D- 79% B-
Trailing 12 Months  
Capital Gain 179.33% 65% D 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.33% 65% D 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.51% 60% D- 62% D
Dividend Return 8.51% 60% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.65% 62% D 35% F
Risk Adjusted Return 15.87% 74% C 50% F
Market Capitalization 1.39B 83% B 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector